> anonymouse wrote in message ...
>>thx for your thoughts so far. it looks like i can't blame this for my
[quoted text clipped - 26 lines]
> Regards
> Old Al
anonymouse wrote in message ...
>that's brilliant al, as i have tried lantus and didn't like it but doc says
>i will be on it at some point. seeing him next monday so i'll mention this
>cov aspect. my hba1c runs around late 6's
. . .(snip). . .
>> I read your "Insulin I" as Insulin Isophane also known as NPH. NPH
>> is a very difficult insulin for a T1 to use. It has the highest
Coefficient
>> of Variation (COV) of any basal insulin on the market. That means
>> fast today, slow tomorrow, medium speed next Tuesday. . . .
[quoted text clipped - 4 lines]
>> Regards
>> Old Al
If you want to plow through research papers which quote measured COV for
the big three: NPH, Lantus and Levemir (Detemir), see below. BTW, I
vote for Levemir so far. I am trying it (and liking it) as part of a
pre-release clinical trial. It's supposed to be generally available in my
area in early April.
Original Paper
http://www.diabetesincontrol.com/issue183/InsulinDetemir.pdf
“. . .the mean durations of insulins detemir and glargine are 14 and 22
hours respectively. . .”
Condensed for Popular Press
http://www.diabetesincontrol.com/modules.php?name=News&file=article&sid=1
“. . .A study presented at the 18th International Diabetes Federation
Congress in Paris in August 2003 reported that among 54 persons with type 1
diabetes given NPH, detemir, or glargine insulin on 4 occasions with glucose
infused to maintain euglycemia, the coefficient of variation of the glucose
infusion was 46% to 68%, 23% to 27%, and 36% to 48%, respectively,
suggesting that the degree of within-subject variability was least with
detemir.. . .”
[The above sentence, an example of moderately mysterious use of the English
Language, translates to:
Within-Subject COV NPH = 46 - 68%
COV Lantus = 36 - 48%
COV Levemir = 23-27% ]
I think I saw some person to person COV quoted in these papers but I'm more
interested in within-subject COV, i.e. what one person can expect from
injection to injection to injection.
More on COV
http://care.diabetesjournals.org/cgi/content/full/24/2/296
“. . . . The high individual variation in absorption rate is one of the
major drawbacks related to current therapy with NPH (3,16). A smaller
intrasubject variability in fasting blood glucose was observed with insulin
detemir, although 65% of the subjects had to apply two injections. The lower
variability together with the reduced action peak (9) could be an important
advantage and facilitate strict metabolic control. More reproducible and
predictable glucose levels throughout the night would minimize the risk of
hypoglycemia and provide better glucose control in the early morning hours.
Because treatment with insulin detemir resulted in higher mean serum glucose
levels during the time interval 23:00-06:00, earlier administration and/or
higher dosing might optimize therapy further. . . . .”
Regards
Old Al